MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Over the last 12 months, insiders at MacroGenics, Inc. have bought $1.8M and sold $5M worth of MacroGenics, Inc. stock.
On average, over the past 5 years, insiders at MacroGenics, Inc. have bought $9.69M and sold $1.9M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BIOTECH TARGET N V (10 percent owner) — $6.89M. HURWITZ EDWARD (director) — $147,300.
The last purchase of 150,000 shares for transaction amount of $669,585 was made by BIOTECH TARGET N V (10 percent owner) on 2023‑10‑02.
2024-04-04 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 51,395 0.0725% | $15.55 | $799,148 | -72.31% | |
2024-03-06 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 19,625 0.0317% | $21.50 | $421,938 | -32.40% | |
2024-03-04 | Sale | Karrels James | SVP, CFO and Secretary | 30,000 0.0481% | $20.50 | $615,000 | -29.54% | |
2024-03-04 | Sale | Risser Eric Blasius | Chief Operating Officer | 41,159 0.0636% | $19.76 | $813,501 | -29.54% | |
2024-03-04 | Sale | Spitznagel Thomas | Sr VP, Technical Ops | 10,000 0.0156% | $20.00 | $200,000 | -29.54% | |
2024-02-26 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 16,124 0.0266% | $17.22 | $277,655 | -12.37% | |
2024-02-07 | Sale | Bonvini Ezio | Sr VP, Research & CSO | 3,334 0.0069% | $18.00 | $60,012 | -11.70% | |
2024-02-05 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 76,251 0.1454% | $16.50 | $1.26M | -8.00% | |
2024-02-01 | Sale | Bonvini Ezio | Sr VP, Research & CSO | 13,316 0.0231% | $15.00 | $199,740 | +1.18% | |
2024-01-19 | Sale | Bonvini Ezio | Sr VP, Research & CSO | 13,316 0.0216% | $12.00 | $159,792 | +27.68% | |
2023-12-20 | Sale | Bonvini Ezio | Sr VP, Research & CSO | 18,880 0.031% | $10.08 | $190,310 | +44.49% | |
2023-10-02 | BIOTECH TARGET N V | 10 percent owner | 150,000 0.2413% | $4.46 | $669,585 | +122.77% | ||
2023-09-07 | BIOTECH TARGET N V | 10 percent owner | 200,000 0.324% | $5.26 | $1.05M | +73.44% | ||
2023-08-30 | HURWITZ EDWARD | director | 15,000 0.0244% | $4.91 | $73,650 | +78.16% | ||
2023-03-10 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 5,372 0.0099% | $6.03 | $32,393 | +19.55% | |
2023-02-14 | BIOTECH TARGET N V | 10 percent owner | 500,000 0.7819% | $5.07 | $2.53M | +15.84% | ||
2023-01-19 | BIOTECH TARGET N V | director | 150,000 0.245% | $5.30 | $794,925 | +10.19% | ||
2022-12-27 | BIOTECH TARGET N V | director | 200,000 0.3249% | $5.61 | $1.12M | +1.33% | ||
2022-12-23 | BIOTECH TARGET N V | director | 200,000 0.3225% | $5.88 | $1.18M | -4.21% | ||
2022-11-22 | BIOTECH TARGET N V | director | 300,000 0.471% | $5.96 | $1.79M | -7.93% |
BIOTECH TARGET N V | 10 percent owner | 9929963 16.0085% | $4.07 | 19 | 0 | <0.0001% |
Karrels James | SVP, CFO and Secretary | 171452 0.3092% | $4.07 | 1 | 3 | +137.87% |
Bonvini Ezio | Sr VP, Research & CSO | 71334 0.115% | $4.07 | 0 | 16 | |
Risser Eric Blasius | Sr VP & Chief Business Officer | 38900 0.0717% | $4.07 | 0 | 26 | |
HURWITZ EDWARD | director | 33074 0.0533% | $4.07 | 1 | 1 | |
Spitznagel Thomas | Sr VP, BPD & Manufacturing | 8316 0% | $4.07 | 0 | 6 | |
Peters Jeffrey Stuart | Senior VP and General Counsel | 0 0% | $4.07 | 0 | 8 | |
ORONSKY ARNOLD L | director | 1708716 2.7547% | $4.07 | 0 | 1 | |
Costa Paulo F | director | 59435 0.0958% | $4.07 | 1 | 0 | +41.83% |
Stein Kathryn E | SVP, Product Dev. & Regulatory | 43205 0.0697% | $4.07 | 0 | 6 | |
Wigginton Jon Marc | Sr VP, Clinical Dev. & CMO | 30000 0.0484% | $4.07 | 0 | 17 | |
Cilinski Lynn | VP, Controller and Treasurer | 1923 0.0031% | $4.07 | 0 | 7 | |
Fust Matthew K | director | 500 0.0008% | $4.07 | 0 | 1 | |
Galbraith Kenneth | director | 0 0% | $4.07 | 1 | 1 | <0.0001% |
Bellevue Group | $146.7M | 15.91 | 9.97M | +0.13% | +$184,721.28 | 2.24 | |
Avoro Capital Advisors Llc | $90.53M | 9.82 | 6.15M | New | +$90.53M | 1.09 | |
BlackRock | $83.85M | 9.09 | 5.7M | -7.23% | -$6.54M | <0.01 | |
State Street | $64.62M | 7.01 | 4.39M | +101.91% | +$32.61M | <0.01 | |
The Vanguard Group | $54.14M | 5.87 | 3.68M | -14.66% | -$9.3M | <0.01 | |
T Rowe Price Investment Management Inc | $40.73M | 4.42 | 2.77M | -50.94% | -$42.29M | 0.03 | |
Frazier Life Sciences Management L P | $36.38M | 3.95 | 2.47M | +2.92% | +$1.03M | 1.87 | |
T. Rowe Price | $35.89M | 3.89 | 2.44M | +8,361.63% | +$35.46M | <0.01 | |
Armistice Capital Llc | $35.33M | 3.83 | 2.4M | -47.51% | -$31.97M | 0.42 | |
RA Capital Management, L.P. | $30.65M | 3.32 | 2.08M | -48.63% | -$29.01M | 0.03 | |
Geode Capital Management | $21.08M | 2.29 | 1.43M | +1.99% | +$411,404.97 | <0.01 | |
ROCK SPRINGS CAPITAL MANAGEMENT, LP | $19.21M | 2.08 | 1.31M | +10.73% | +$1.86M | 0.49 | |
Dimensional Fund Advisors | $15.47M | 1.68 | 1.05M | -13.47% | -$2.41M | <0.01 | |
JPMorgan Chase | $15.15M | 1.64 | 1.03M | -9.31% | -$1.56M | <0.01 | |
Wasatch Advisors | $14.57M | 1.58 | 989,579 | -23.74% | -$4.53M | 0.08 | |
Northern Trust | $10.78M | 1.17 | 732,414 | -5.43% | -$619,196.80 | <0.01 | |
Renaissance Technologies | $10.53M | 1.14 | 715,027 | -6.35% | -$713,906.61 | 0.02 | |
Pinnacle Associates, Ltd. | $9.53M | 1.03 | 647,235 | -5.92% | -$599,766.39 | 0.15 | |
Nuveen | $8.09M | 0.88 | 549,640 | -9.48% | -$847,445.14 | <0.01 | |
Susquehanna International Group | $7.83M | 0.85 | 531,922 | +563.06% | +$6.65M | 0.01 | |
Charles Schwab | $7.7M | 0.84 | 522,946 | -37.26% | -$4.57M | <0.01 | |
Integral Health Asset Management Llc | $7.36M | 0.8 | 500,000 | +11.11% | +$736,000.00 | 0.73 | |
Silverarc Capital Management Llc | $7.04M | 0.76 | 478,079 | -62.02% | -$11.49M | 2.07 | |
Acadian Asset Management | $6.97M | 0.76 | 473,413 | -55.24% | -$8.6M | 0.02 | |
Panagora | $6.82M | 0.74 | 463,430 | +16.16% | +$949,233.98 | 0.03 | |
Federated Hermes | $6.68M | 0.72 | 453,732 | -43.52% | -$5.15M | 0.02 | |
Macquarie Group | $6.18M | 0.67 | 420,000 | 0% | +$0 | 0.01 | |
Connor Clark & Lunn Investment Management Ltd | $6.16M | 0.67 | 418,282 | +71.29% | +$2.56M | 0.01 | |
Jane Street Capital | $5.57M | 0.6 | 378,523 | +419.67% | +$4.5M | 0.01 | |
Perceptive Advisors | $5.57M | 0.6 | 378,327 | -38.17% | -$3.44M | <0.01 | |
Woodline Partners LP | $5.38M | 0.58 | 365,425 | New | +$5.38M | 0.05 | |
Citadel Advisors LLC | $5.36M | 0.58 | 364,234 | +99.6% | +$2.68M | <0.01 | |
Rafferty Asset Management Llc | $5.19M | 0.56 | 352,695 | +272.31% | +$3.8M | 0.02 | |
Goldman Sachs | $5.1M | 0.55 | 346,325 | -43.96% | -$4M | <0.01 | |
Ikarian Capital LLC | $4.68M | 0.51 | 318,167 | New | +$4.68M | 1.34 | |
Franklin Templeton Investments | $4.64M | 0.5 | 315,272 | +445.01% | +$3.79M | <0.01 | |
Bank of America | $4.58M | 0.5 | 310,900 | +118.3% | +$2.48M | <0.0001 | |
Citigroup | $4.49M | 0.49 | 305,076 | +556.49% | +$3.81M | <0.01 | |
Commodore Capital, LP | $4.34M | 0.47 | 295,020 | New | +$4.34M | 0.31 | |
UBS | $3.8M | 0.41 | 258,359 | +94.24% | +$1.85M | <0.01 | |
BNY Mellon | $3.68M | 0.4 | 249,707 | -5.8% | -$226,172.80 | <0.01 | |
Qube Research & Technologies | $3.63M | 0.39 | 246,483 | +706.92% | +$3.18M | <0.01 | |
Wellington Management Company | $3.62M | 0.39 | 245,831 | +3.24% | +$113,461.78 | <0.01 | |
Td Asset Management Inc | $3.14M | 0.34 | 213,448 | +184.41% | +$2.04M | <0.01 | |
Morgan Stanley | $3.12M | 0.34 | 211,948 | -39.65% | -$2.05M | <0.0001 | |
Banque Pictet Cie Sa | $3.07M | 0.33 | 208,698 | New | +$3.07M | 0.03 | |
Jacobs Levy Equity Management | $2.18M | 0.24 | 148,018 | +28.73% | +$486,334.09 | 0.01 | |
Hudson Bay Capital Management LP | $1.92M | 0.21 | 130,133 | +164.54% | +$1.19M | 0.02 | |
The Manufacturers Life Insurance Company | $1.76M | 0.19 | 119,549 | +432.18% | +$1.43M | <0.01 | |
ClariVest Asset Management LLC | $1.74M | 0.19 | 117,919 | -36.89% | -$1.01M | 0.18 |